These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 7207885)

  • 21. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
    Kontoghiorghes GJ
    Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Desferrioxamine in patients with hemochromatosis and hemosiderosis].
    Maspes V; Tamigaki M; Gomes ZJ; Jamra M
    Rev Hosp Clin Fac Med Sao Paulo; 1966; 21(4):181-95. PubMed ID: 5918167
    [No Abstract]   [Full Text] [Related]  

  • 23. [Treatment of post-transfusion iron overload by deferoxamine].
    de Montalembert M; Llados A; Hannedouche T; Girot R
    Arch Fr Pediatr; 1989 Feb; 46(2):99-105. PubMed ID: 2735804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hemochromatosis and vitamin C.
    Herbert V
    Ann Intern Med; 1999 Sep; 131(6):475-6. PubMed ID: 10498572
    [No Abstract]   [Full Text] [Related]  

  • 25. [Use of desferrioxamine B in normal subjects and in patients with increased iron storage].
    Muranda M; Velasco M; Giménez E; Ruiz J; Bastías E; Rodriguez J; Etcheverry R; Guzmán C; Regonesi C; Janklevich S
    Rev Med Chil; 1965 Apr; 93(4):127-33. PubMed ID: 5832943
    [No Abstract]   [Full Text] [Related]  

  • 26. [Iron-chelating treatment].
    Vullo C; Di Palma A; De Sanctis V; Borgatti L; Atti G
    Haematologica; 1989 Oct; 74(5 Suppl):241-51. PubMed ID: 2512211
    [No Abstract]   [Full Text] [Related]  

  • 27. Chelation therapy for the treatment of thalassemia.
    Graziano JH; Cerami A
    Semin Hematol; 1977 Jan; 14(1):127-34. PubMed ID: 318766
    [No Abstract]   [Full Text] [Related]  

  • 28. Desferal therapy in iron storage disease.
    Thompson RB; Owen DM; Bell WN
    Am J Med Sci; 1967 Apr; 253(4):453-60. PubMed ID: 6021380
    [No Abstract]   [Full Text] [Related]  

  • 29. [The value of nuclear magnetic resonance in the study of iron overload in thalassemia patients].
    Perrimond H; Chagnon C; Moulanier I; Michel G; Guidicelli H; Bernard PJ
    Ann Pediatr (Paris); 1991 Mar; 38(3):175-84. PubMed ID: 2039185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Treatment of primary idiopathic hemochromatosis and secondary hemosiderosis].
    Strohmeyer G
    Dtsch Med Wochenschr; 1974 Nov; 99(45):2295-9. PubMed ID: 4448138
    [No Abstract]   [Full Text] [Related]  

  • 31. Thalassemia.
    Brown EB
    Prog Clin Biol Res; 1983; 127():33-42. PubMed ID: 6889403
    [No Abstract]   [Full Text] [Related]  

  • 32. Effect of phenylhydrazine-induced haemolysis on the urinary excretion of iron after desferrioxamine.
    Cumming RL; Goldberg A; Morrow J; Smith JA
    Lancet; 1967 Jan; 1(7481):71-4. PubMed ID: 4163055
    [No Abstract]   [Full Text] [Related]  

  • 33. Hyperpigmentation and secondary hemochromatosis: a novel treatment with extracorporeal chelation.
    Held JL; Yankiver B; Kohn SR
    J Am Acad Dermatol; 1993 Feb; 28(2 Pt 1):253-4. PubMed ID: 8432923
    [No Abstract]   [Full Text] [Related]  

  • 34. Desferrioxamine therapy induces clearance of iron deposits after bone marrow transplantation for thalassemia: case report.
    Giardini C; La Nasa G; Contu L; Galimberti M; Polchi P; Angelucci E; Baronciani D; Barbanti I; Muretto P; Lucarelli G
    Bone Marrow Transplant; 1993; 12 Suppl 1():108-10. PubMed ID: 8374548
    [No Abstract]   [Full Text] [Related]  

  • 35. Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
    Nijjar PS; Vongooru H; Tamene A; Valeti U; Masri C
    Minn Med; 2015 Jul; 98(7):47. PubMed ID: 26267924
    [No Abstract]   [Full Text] [Related]  

  • 36. Editorial: Thalassemia major: a problem of iron overload.
    Stockman JA; Oski FA
    Ann Intern Med; 1974 Aug; 81(2):262-3. PubMed ID: 4846109
    [No Abstract]   [Full Text] [Related]  

  • 37. An oral treatment for iron overload in thalassemia?
    Kowdley KV; Tavill AS
    Hepatology; 1996 Feb; 23(2):380-2. PubMed ID: 8591869
    [No Abstract]   [Full Text] [Related]  

  • 38. Clinical studies on iron chelation in patients with thalassemia major.
    Freedman MH; Olivieri N; Benson L; Liu P; McClelland R; St Louis P; Templeton D; Koren G
    Haematologica; 1990; 75 Suppl 5():74-83. PubMed ID: 2086384
    [No Abstract]   [Full Text] [Related]  

  • 39. [Use of desferal and some data on hemosiderosis in hypo- and aplastic anemias].
    Fainshtein FE; Trubina NS; Sobaleva IuG; Rozanova NS; Voronina AN
    Probl Gematol Pereliv Krovi; 1968 Aug; 13(8):31-8. PubMed ID: 5736846
    [No Abstract]   [Full Text] [Related]  

  • 40. Glucose tolerance and chelation therapy in patients with thalassaemia major.
    Capra L; Atti G; De Sanctis V; Candini G
    Haematologica; 1983; 68(1):63-8. PubMed ID: 6404709
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.